Medlive Technology Co., Ltd.
0.74
EUR
0.00
(0.00%)
ISIN
KYG5961B1041
CUSIP
G5961B104
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Li Ping Tian
- Full Time Employees
- 724
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Yimaitong Mansion Beijing BE China
- IPO Date
- Jul 15, 2021
- Website
- medlive.cn
- Similar Companies
- Business
- Medlive Technology Co., Ltd. Medlive Technology Co., Ltd. operates an online professional physician platform primarily in Mainland China and internationally, offering precision marketing and corporate solutions; medical knowledge solutions; and intelligent patient management solutions to pharmaceutical companies, medical device firms, healthcare professionals, and patients. Precision marketing solutions include digital detailing, digital marketing consulting, digital content creation, and application software development, while corporate solutions encompass digital market research, electronic data capture, clinical data management systems, real-world studies support, and patient recruitment services; medical knowledge solutions provide continuing medical education, clinical decision support, clinical guidelines, disease knowledge bases, medication references, video platforms, examination preparation tools, and AI-assisted writing and Q&A systems; intelligent patient management solutions deliver single-disease management with disease knowledge dissemination, treatment compliance monitoring, patient education, online consultations, prescriptions, and chronic disease management for conditions such as Parkinson's, lymphoma, stroke, diabetes, breast cancer, lung cancer, and ovarian cancer, along with internet hospital services, research and development support, medical exhibition conferences, and guideline publications. Founded in 1996 and headquartered in Beijing, China, the company, formerly known as Kingyee Co., Limited until its name change in 2021, serves over 7 million registered physician users including more than 4 million licensed physicians, with average monthly active users reaching 2.65 million in 2024, and operates mainly in the domestic market while expanding overseas. Recent developments include a 35.5% revenue increase to RMB558.5 million in 2024 driven by precision marketing growth, with customer numbers rising 25.3% to 228 and marketed products up 31.1% to 506; AI advancements such as a self-developed medical vertical large model approved by regulators, AI Q&A systems with diagnosis maps and rational medication tools, and AI-assisted writing improving efficiency by 60%; addition of over 3,100 clinical guidelines to reach 31,100 total, 500 new disease entries, and 15,000 videos; approval as a postdoctoral research workstation; expansion of clinical research in oncology, hematology, neurology, pediatrics, and cardiovascular fields; and strategic collaborations with the Chinese Medical Association, NCCN, ASCO, and others, alongside prior acquisitions like 50% of Beijing SCMedcon in 2023 and partnerships with CSCO and Hainan Boao Lecheng.